NCT02121080View on ClinicalTrials.gov

Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Healthy Volunteers
Interventions
DRUG

REGN2222(SAR438584)

DRUG

placebo

Trial Locations (3)

Unknown

Daytona Beach

Evansville

Dallas

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02121080 - Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter